Zoetis Inc. (NYSE:ZTS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. BofA Downgrades Zoetis (ZTS) to Neutral, Cuts Price Target Budimir Jevtic/Shutterstock.com On December 15, BofA downgraded Zoetis Inc. (NYSE:ZTS) to Neutral from Buy and lowered its price target to $135 from $165. In other news, on December 5, Zoetis Inc. (NYSE:ZTS) announced that Health Canada approved Portela™ (relfovetmab injection) for the relief of pain linked to osteoarthritis, or OA, in cats. Portela is d ...